Freedom from Structural Valve Deterioration

Author Year No. of
Patients
Type of
Study
Type of
Valve
Mean Age
at Implant
Mean
Follow-Up (yrs)
5 years
(%)
10 years
(%)
15 years
(%)
20 years
(%)
25 years
(%)
Linearized rate
(% per pt year)
Khan et al, 1998 248 Retrospective Hancock Porcine 64 7.3 - - - - - -
Poirier et al, 1998 149 Prospective Follow-Up *CE bovine pericardial 65 4.8 100 81 - - - 1.2
Jamieson et al, 1999 1266 Prospective Follow-Up CE supra-annular porcine 64 7.3 - - - - - -
Jamieson et al, 1999 429 Prospective Follow-Up CE perimount pericardial 61 7.3 - - - - - -
David et al, 2001 310 Prospective Follow-Up Hancock II porcine 65 6.9 100 86 66 - - -
Marchand et al, 2001 435 Prospective Follow-Up CE perimount pericardial 61 8.1 - - 66 (14yr) - - -
Rizzoli et al, 2006 484 Prospective Follow-Up Hancock II porcine 66 12 100 93 71 - - -
Jamieson et al, 2009 1135 Prospective Follow-Up CE supra-annular porcine 65 6.4 - - 31 20 (18yr) - 6.2 (<50 yo)
4.7 (51-60 yo)
3.4 (61-70 yo)
0.9 (>70 yo)
Myken et al, 2009 194 Prospective Follow-Up St. Jude Medical Biocor 65 6.2 - - - 79** - 0.9
Riess et al, 2010 47 Prospective Follow-Up Medtronic Mosaic porcine 67 8.2 100 (4yr) 100 (8yr) 94 (13yr) - - 0.3
Jamieson et al, 2011 232 Prospective Follow-Up Medtronic Mosaic porcine 67 7.3 99** 95** 92** - - -
Aaron J. Weiss M.D., Stephen M. Spindel M.D., and Farzan Filsoufi M.D.
* CE = Carpentier-Edwards
** Values correspond to actuarial freedom from reoperation because of structural valve deterioration (SVD). Patients that had SVD without reoperation were not detailed in this study.
  1. Khan SS, Chaux A, Blanche C, et al. A 20-year experience with the Hancock porcine xenograft in the elderly. Ann Thorac Surg 1998;66:S35-9.
  2. Poirier NC, Pelletier LC, Pellerin M, et al. 15-year experience with the Carpentier-Edwards pericardial bioprosthesis. Ann Thorac Surg 1998;66:S57-61.
  3. Jamieson WR, Marchand MA, Pelletier CL, et al. Structural valve deterioration in mitral replacement surgery: comparison of Carpentier-Edwards supra-annular porcine and perimount pericardial bioprostheses. J Thorac Cardiovasc Surg 1999;118:297-304.
  4. David TE, Ivanov J, Armstrong S, et al. Late results of heart valve replacement with the Hancock II bioprosthesis. J Thorac Cardiovasc Surg 2001;121:268-77.
  5. Marchand MA, Aupart MR, Norton R, et al. Fifteen-year experience with the mitral Carpentier-Edwards PERIMOUNT pericardial bioprosthesis. Ann Thorac Surg 2001;71:S236-9.
  6. Rizzoli G, Mirone S, Ius P, et al. Fifteen-year results with the Hancock II valve: a multicenter experience. J Thorac Cardiovasc Surg 2006;132:602-9, 609 e1-4.
  7. Jamieson WR, Gudas VM, Burr LH, et al. Mitral valve disease: if the mitral valve is not reparable/failed repair, is bioprosthesis suitable for replacement? Eur J Cardiothorac Surg 2009;35:104-10.
  8. Myken PS, Bech-Hansen O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg 2009;137:76-81.
  9. Riess FC, Cramer E, Hansen L, et al. Clinical results of the Medtronic Mosaic porcine bioprosthesis up to 13 years. Eur J Cardiothorac Surg 2010;37:145-53.
  10. Jamieson WR, Riess FC, Raudkivi PJ, et al. Medtronic Mosaic porcine bioprosthesis: assessment of 12-year performance. J Thorac Cardiovasc Surg 2011;142:302-7 e2.